These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 23427297)

  • 1. Tandutinib inhibits the Akt/mTOR signaling pathway to inhibit colon cancer growth.
    Ponnurangam S; Standing D; Rangarajan P; Subramaniam D
    Mol Cancer Ther; 2013 May; 12(5):598-609. PubMed ID: 23427297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK-4 inhibitor P276 sensitizes pancreatic cancer cells to gemcitabine-induced apoptosis.
    Subramaniam D; Periyasamy G; Ponnurangam S; Chakrabarti D; Sugumar A; Padigaru M; Weir SJ; Balakrishnan A; Sharma S; Anant S
    Mol Cancer Ther; 2012 Jul; 11(7):1598-608. PubMed ID: 22532602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tunicamycin inhibits colon carcinoma growth and aggressiveness via modulation of the ERK-JNK-mediated AKT/mTOR signaling pathway.
    You S; Li W; Guan Y
    Mol Med Rep; 2018 Mar; 17(3):4203-4212. PubMed ID: 29344654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new discovery: Total Bupleurum saponin extracts can inhibit the proliferation and induce apoptosis of colon cancer cells by regulating the PI3K/Akt/mTOR pathway.
    Zhang X; Liu Z; Chen S; Li H; Dong L; Fu X
    J Ethnopharmacol; 2022 Jan; 283():114742. PubMed ID: 34655668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-immunosuppressive triazole-based small molecule induces anticancer activity against human hormone-refractory prostate cancers: the role in inhibition of PI3K/AKT/mTOR and c-Myc signaling pathways.
    Leu WJ; Swain ShP; Chan SH; Hsu JL; Liu SP; Chan ML; Yu CC; Hsu LC; Chou YL; Chang WL; Hou DR; Guh JH
    Oncotarget; 2016 Nov; 7(47):76995-77009. PubMed ID: 27769069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.
    Hong SW; Jung KH; Lee HS; Choi MJ; Son MK; Zheng HM; Hong SS
    Cancer Sci; 2012 Nov; 103(11):1929-37. PubMed ID: 22909393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity.
    Ibáñez E; Agliano A; Prior C; Nguewa P; Redrado M; González-Zubeldia I; Plano D; Palop JA; Sanmartín C; Calvo A
    Curr Med Chem; 2012; 19(18):3031-43. PubMed ID: 22455594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quercetin inhibits angiogenesis mediated human prostate tumor growth by targeting VEGFR- 2 regulated AKT/mTOR/P70S6K signaling pathways.
    Pratheeshkumar P; Budhraja A; Son YO; Wang X; Zhang Z; Ding S; Wang L; Hitron A; Lee JC; Xu M; Chen G; Luo J; Shi X
    PLoS One; 2012; 7(10):e47516. PubMed ID: 23094058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
    Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
    Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
    Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of Torin2, an ATP-competitive inhibitor of mTOR, ATM, and ATR.
    Liu Q; Xu C; Kirubakaran S; Zhang X; Hur W; Liu Y; Kwiatkowski NP; Wang J; Westover KD; Gao P; Ercan D; Niepel M; Thoreen CC; Kang SA; Patricelli MP; Wang Y; Tupper T; Altabef A; Kawamura H; Held KD; Chou DM; Elledge SJ; Janne PA; Wong KK; Sabatini DM; Gray NS
    Cancer Res; 2013 Apr; 73(8):2574-86. PubMed ID: 23436801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anti-esophageal cancer cell activity by a novel tyrosine/phosphoinositide kinase inhibitor PP121.
    Peng Y; Zhou Y; Cheng L; Hu D; Zhou X; Wang Z; Xie C; Zhou F
    Biochem Biophys Res Commun; 2015 Sep; 465(1):137-44. PubMed ID: 26235881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A.
    Kuo YH; Chiang EI; Chao CY; Rodriguez RL; Chou PY; Tsai SY; Pai MH; Tang FY
    Mol Cancer Ther; 2017 Mar; 16(3):480-493. PubMed ID: 27956520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.
    Jung KH; Choi MJ; Hong S; Lee H; Hong SW; Zheng HM; Lee HS; Hong S; Hong SS
    Cancer Lett; 2012 Mar; 316(2):187-95. PubMed ID: 22182943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxymatrine synergistically enhances antitumor activity of oxaliplatin in colon carcinoma through PI3K/AKT/mTOR pathway.
    Liu Y; Bi T; Wang Z; Wu G; Qian L; Gao Q; Shen G
    Apoptosis; 2016 Dec; 21(12):1398-1407. PubMed ID: 27671687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inositol Hexaphosphate Inhibits Proliferation and Induces Apoptosis of Colon Cancer Cells by Suppressing the AKT/mTOR Signaling Pathway.
    Kapral M; Wawszczyk J; Jesse K; Paul-Samojedny M; Kuśmierz D; Węglarz L
    Molecules; 2017 Oct; 22(10):. PubMed ID: 28972559
    [No Abstract]   [Full Text] [Related]  

  • 17. miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway.
    Zhang X; Shi H; Tang H; Fang Z; Wang J; Cui S
    Int J Mol Med; 2015 May; 35(5):1301-8. PubMed ID: 25760926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells.
    Lou YF; Zou ZZ; Chen PJ; Huang GB; Li B; Zheng DQ; Yu XR; Luo XY
    PLoS One; 2014; 9(5):e97719. PubMed ID: 24874286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models.
    Xu S; Li S; Guo Z; Luo J; Ellis MJ; Ma CX
    Mol Cancer Ther; 2013 Aug; 12(8):1665-75. PubMed ID: 23689832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of aldose reductase prevents growth factor-induced G1-S phase transition through the AKT/phosphoinositide 3-kinase/E2F-1 pathway in human colon cancer cells.
    Ramana KV; Tammali R; Srivastava SK
    Mol Cancer Ther; 2010 Apr; 9(4):813-24. PubMed ID: 20354121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.